Why the study?
Do serum cardiac biomarkers (troponin I and NT-proBNP) indicate subclinical cardiac strain in women with normal LVEF receiving trastuzumab?
Do serum cardiac biomarkers (troponin I and NT-proBNP) indicate subclinical cardiac strain in women with normal LVEF receiving trastuzumab?
NT-proBNP, but not troponin I, is frequently elevated in women with normal LVEF receiving trastuzumab, providing biochemical evidence of subclinical cardiac strain.
No takes yet. Share an insight, caveat, or question.
NT-proBNP elevations may indicate subclinical strain during trastuzumab; leaves open whether routine monitoring improves outcomes in preserved LVEF.
Goel et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: